LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next-Gen IVD LC-MS/MS System 5X More Sensitive for Quantifying Analytes in Saliva, Breath and Dried Blood Spots

By LabMedica International staff writers
Posted on 06 Apr 2023
Print article
Image: The new MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (Photo courtesy of Waters)
Image: The new MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (Photo courtesy of Waters)

As energy expenses increase dramatically and laboratory spaces remain in high demand, the need for an analytical instrument that can perform complex trace analyte quantification and increase in-house testing while also reducing energy consumption and saving lab space has become critical. Now, an extremely compact and sustainable analytical instrument accurately quantifies trace analytes with outstanding precision. This powerful instrument can improve patient care, generate cost savings, and meet a laboratory's unique analytical workflow requirements with its vast array of customizable options.

Waters Corporation (Milford, MA, USA) has introduced its next-generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications. The new MassTrak LC-MS/MS IVD system now comprises the ACQUITY UPLC I-Class PLUS liquid chromatography instrument and the Xevo TQ Absolute IVD mass spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to provide fast and precise sample analysis to improve mass spectrometer sensitivity and simplify complex sample characterization. The Xevo TQ Absolute IVD System is more consistent than other tandem quadrupole-mass spectrometry (TQ-MS) systems, with a user-friendly design that maximizes service uptime. Additionally, it is 45% smaller and uses 50% less nitrogen gas and electricity than comparable TQ-MS systems, making it ideal for hospital and commercial labs seeking to reduce energy consumption and save space.

The Xevo TQ Absolute IVD mass spectrometer offers exceptional analytical performance, with up to five times greater sensitivity for quantifying clinical analytes compared to other commercial instruments available. This heightened sensitivity allows clinical laboratories to detect and measure trace-level analytes within a sample, reaching detection levels previously unattainable. This capability expands the testing capabilities of clinical laboratories, making it possible to work with lower volume samples obtained from less invasive assays such as saliva, breath, and dried blood spots. Additionally, the system empowers clinical laboratories to expand their test menu to include multiplex panels and large molecules.

“Waters’ MassTrak IVD systems gives clinical diagnostic laboratories highly precise and flexible options that ultimately enable clinicians to provide better patient care,” said Jianqing Bennett, Waters Corporation Senior Vice President of the Waters Clinical Business Unit. “Adding the Xevo TQ Absolute IVD to the MassTrak IVD family offers customers class-leading sensitivity and analytical performance. Waters is uniquely positioned to enable clinical laboratories to develop reliable test methods for difficult analytes, helping them expand their capabilities to manage emerging remote sampling techniques.”

Related Links:
Waters Corporation 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more